{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:04:06Z","timestamp":1794870246265,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p><jats:italic>Helicobacter pylori<\/jats:italic> (<jats:italic>H. pylori<\/jats:italic>) is affecting half of the globe. It is considered a main causative organism of chronic gastritis, peptic ulcer disease, and different gastric maliganacies. It has been also correlated to extraintestinal diseases, including refractory iron deficiency anaemia, vitamin B12 deficiency, and immune thrombocytopenic purpura. The misuse of antibiotics during the coronavirus diseases 2019 (COVID-19) pandemic time can affect <jats:italic>H. pylori<\/jats:italic> eradication rates. Our aim was to compare the efficacy of clarithromycin versus levofloxacin-based regimens for <jats:italic>H. pylori<\/jats:italic> treatment in na\u00efve patients after the COVID-19 pandemic misuse of antibiotics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 270 na\u00efve <jats:italic>H. pylori<\/jats:italic> infected patients with previous treatment for COVID-19 more than 3 months before enrolment were recruited. Patients were randomized to receive either clarithromycin, esomeprazole, and amoxicillin, or levofloxacin, esomeprazole, and amoxicillin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 270 na\u00efve <jats:italic>H. pylori<\/jats:italic> infected patients with previous treatment for COVID-19 more than 3 months before enrolment were included, 135 in each arm. In total, 19 patients in the clarithromycin group and 18 patients in the levofloxacin group stopped treatment after 2\u20134 days because of side effects or were lost for follow-up. Finally, 116 subjects in the clarithromycin group and 117 in the levofloxacin group were assessed. The eradication rates in intention to treat (ITT) and per protocol (PP) analyses were: group I, 55.56% and 64.66%; and Group II, 64.44% and 74.36% respectively (p\u2009=\u20090.11).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>As COVID-19 pandemic has moved forward fast, high resistance rates of <jats:italic>H. pylori<\/jats:italic> to both clarithromycin and levofloxacin were developed after less than two years from the start of the pandemic. Molecular &amp; genetic testing is highly recommended to identify antimicrobial resistance patterns. Strategies to prevent antibiotic misuse in the treatment of COVID-19 are needed to prevent more antibiotic resistance.<\/jats:p>\n                <jats:p><jats:italic>Trial Registration<\/jats:italic>: The trial was registered on Clinicaltrials.gov NCT05035186. Date of registration is 2-09-2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-07993-8","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T04:36:27Z","timestamp":1674275787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Helicobacter pylori\u00a0eradication rates using clarithromycin and levofloxacin-based regimens in patients with previous COVID-19 treatment: a randomized clinical trial"],"prefix":"10.1186","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct05035186","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0957-0977","authenticated-orcid":false,"given":"Ahmed","family":"Kamal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-706X","authenticated-orcid":false,"given":"Ramy Mohamed","family":"Ghazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1046-643X","authenticated-orcid":false,"given":"Dalia","family":"Sherief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-9502","authenticated-orcid":false,"given":"Aliaa","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4421-0205","authenticated-orcid":false,"given":"Walid Ismail","family":"Ellakany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"7993_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fcimb.2016.00159","volume":"6","author":"Y Huang","year":"2016","unstructured":"Huang Y, Wang Q-l, Cheng D-d, Xu W-T, Lu N-H. Adhesion and Invasion of gastric mucosa epithelial cells by Helicobacter pylori. Front Cell Infect Microbiol. 2016;6:159.","journal-title":"Front Cell Infect Microbiol"},{"key":"7993_CR2","first-page":"212","volume":"112","author":"WD Chey","year":"2017","unstructured":"Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Off J Am Coll Gastroenterology|ACG. 2017;112:212\u201339.","journal-title":"Off J Am Coll Gastroenterology|ACG"},{"key":"7993_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1055\/a-0859-1883","volume":"51","author":"P Pimentel-Nunes","year":"2019","unstructured":"Pimentel-Nunes P, Lib\u00e2nio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): european society of gastrointestinal endoscopy (ESGE), european Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51:365\u201388.","journal-title":"Endoscopy"},{"key":"7993_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1523-5378.2012.00983.x","volume":"17","author":"M Bani\u0107","year":"2012","unstructured":"Bani\u0107 M, Franceschi F, Babi\u0107 Z, Gasbarrini A. Extragastric manifestations of Helicobacter pylori Infection. Helicobacter. 2012;17:49\u201355.","journal-title":"Helicobacter"},{"key":"7993_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1542-3565(04)00458-6","volume":"2","author":"C Bilardi","year":"2004","unstructured":"Bilardi C, Dulbecco P, Zentilin P, Reglioni S, Iiritano E, Parodi A, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol. 2004;2:997\u20131002.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7993_CR6","doi-asserted-by":"publisher","first-page":"e85620","DOI":"10.1371\/journal.pone.0085620","volume":"9","author":"MC Peedikayil","year":"2014","unstructured":"Peedikayil MC, AlSohaibani FI, Alkhenizan AH. Levofloxacin-based first-line therapy versus Standard First-Line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. PLoS ONE. 2014;9:e85620.","journal-title":"PLoS ONE"},{"key":"7993_CR7","doi-asserted-by":"crossref","unstructured":"O\u2019Connor JPA, Taneike I, O\u2019Morain C, Review. Improving compliance with Helicobacter pylori eradication therapy: when and how? Therap Adv Gastroenterol. 2009;273\u20139.","DOI":"10.1177\/1756283X09337342"},{"key":"7993_CR8","doi-asserted-by":"publisher","first-page":"621791","DOI":"10.3389\/fmicb.2020.621791","volume":"11","author":"J Li","year":"2021","unstructured":"Li J, Deng J, Wang Z, Li H, Wan C. Antibiotic resistance of Helicobacter pylori strains isolated from pediatric patients in Southwest China. Front Microbiol. 2021;11:621791.","journal-title":"Front Microbiol"},{"key":"7993_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","volume":"62","author":"F Megraud","year":"2013","unstructured":"Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34\u201342.","journal-title":"Gut"},{"key":"7993_CR10","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S0140-6736(21)00461-X","volume":"397","author":"CC Butler","year":"2021","unstructured":"Butler CC, Dorward J, Yu L-M, Gbinigie O, Hayward G, Saville BR, et al. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;397:1063\u201374.","journal-title":"Lancet"},{"key":"7993_CR11","doi-asserted-by":"publisher","first-page":"e649570","DOI":"10.1155\/2012\/649570","volume":"2012","author":"J-Y Min","year":"2012","unstructured":"Min J-Y, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators Inflamm. 2012;2012:e649570.","journal-title":"Mediators Inflamm."},{"key":"7993_CR12","doi-asserted-by":"crossref","unstructured":"Taylor L. Covid-19: antimicrobial misuse in Americas sees drug resistant infections surge, says WHO. BMJ. 2021;375:n2845.","DOI":"10.1136\/bmj.n2845"},{"key":"7993_CR13","doi-asserted-by":"publisher","first-page":"e14081","DOI":"10.1111\/ijcp.14081","volume":"75","author":"AA Elsayed","year":"2021","unstructured":"Elsayed AA, Darwish SF, Zewail MB, Mohammed M, Saeed H, Rabea H. Antibiotic misuse and compliance with infection control measures during COVID-19 pandemic in community pharmacies in Egypt. Int J Clin Pract. 2021;75:e14081.","journal-title":"Int J Clin Pract"},{"key":"7993_CR14","doi-asserted-by":"publisher","first-page":"11221","DOI":"10.3748\/wjg.v21.i40.11221","volume":"21","author":"YK Wang","year":"2015","unstructured":"Wang YK, Kuo FC, Liu CJ, Wu MC, Shih HY, Wang SS, et al. Diagnosis of Helicobacter pylori infection: current options and developments. World J Gastroenterol. 2015;21:11221\u201335.","journal-title":"World J Gastroenterol"},{"key":"7993_CR15","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.3748\/wjg.v25.i34.5097","volume":"25","author":"E Ierardi","year":"2019","unstructured":"Ierardi E, Losurdo G, Fortezza RFL, Principi M, Barone M, Leo AD. Optimizing proton pump inhibitors in Helicobacter pylori treatment: old and new tricks to improve effectiveness. World J Gastroenterol. 2019;25:5097\u2013104.","journal-title":"World J Gastroenterol"},{"key":"7993_CR16","first-page":"e14872","volume":"13","author":"M Hafeez","year":"2021","unstructured":"Hafeez M, Qureshi ZA, Khattak AL, Saeed F, Asghar A, Azam K, et al. Helicobacter Pylori eradication therapy: still a challenge. Cureus. 2021;13:e14872.","journal-title":"Cureus"},{"key":"7993_CR17","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1001\/archinte.160.9.1285","volume":"160","author":"WL Peterson","year":"2000","unstructured":"Peterson WL, Fendrick AM, Cave DR, Peura DA, Garabedian-Ruffalo SM, Laine L. Helicobacter pylori-related disease: guidelines for testing and treatment. Arch Intern Med. 2000;160:1285\u201391.","journal-title":"Arch Intern Med"},{"key":"7993_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/IDR.S153617","volume":"11","author":"DS Nayar","year":"2018","unstructured":"Nayar DS. Current eradication rate of Helicobacter pylori with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area. Infect Drug Resist. 2018;11:205\u201311.","journal-title":"Infect Drug Resist"},{"key":"7993_CR19","first-page":"CD008337","volume":"2013","author":"Y Yuan","year":"2013","unstructured":"Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;2013:CD008337.","journal-title":"Cochrane Database Syst Rev."},{"key":"7993_CR20","doi-asserted-by":"publisher","first-page":"f4587","DOI":"10.1136\/bmj.f4587","volume":"347","author":"L Gatta","year":"2013","unstructured":"Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587.","journal-title":"BMJ"},{"key":"7993_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13099-022-00502-3","volume":"14","author":"ET Azab","year":"2022","unstructured":"Azab ET, Thabit AK, McKee S, Al-Qiraiqiri A. Levofloxacin versus clarithromycin for Helicobacter pylori eradication: are 14\u00a0day regimens better than 10\u00a0day regimens? Gut Pathog. 2022;14:24.","journal-title":"Gut Pathog"},{"key":"7993_CR22","doi-asserted-by":"publisher","first-page":"932478","DOI":"10.1155\/2013\/932478","volume":"2013","author":"W-C Tai","year":"2013","unstructured":"Tai W-C, Chiu C-H, Liang C-M, Chang K-C, Kuo C-M, Chiu Y-C, et al. Ten-day versus 14-Day levofloxacin-containing triple therapy for second-line anti-Helicobacter pylori eradication in Taiwan. Gastroenterol Res Pract. 2013;2013:932478.","journal-title":"Gastroenterol Res Pract"},{"key":"7993_CR23","doi-asserted-by":"publisher","first-page":"500","DOI":"10.21608\/zumj.2019.8141.10510","volume":"25","author":"NG Elantouny","year":"2019","unstructured":"Elantouny NG, Abo Bakr AA, EL-Sokkary RH, Elshahat YE. Levofloxacin versus clarithromycin-based therapy for eradication of Helicobacter pylori infection: a comparative study. Zagazig Univ Med J. 2019;25:500\u20137.","journal-title":"Zagazig Univ Med J"},{"key":"7993_CR24","doi-asserted-by":"publisher","first-page":"hcaa063.021","DOI":"10.1093\/qjmed\/hcaa063.021","volume":"113","author":"Y Awad","year":"2020","unstructured":"Awad Y, Eldeeb M, Fathi M, Mahmoud N, Morsy R. Helicobacter pylori antibiotic resistance patterns among Egyptian children and predictors of resistance. QJM-Int J Med. 2020;113:hcaa063.021.","journal-title":"QJM-Int J Med."},{"key":"7993_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pharmthera.2021.107930","volume":"228","author":"YL Ng","year":"2021","unstructured":"Ng YL, Salim CK, Chu JJH. Drug repurposing for COVID-19: approaches, challenges and promising candidates. Pharmacol Ther. 2021;228:23.","journal-title":"Pharmacol Ther"},{"key":"7993_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.5005\/jp-journals-10071-23862","volume":"25","author":"SK Garg","year":"2021","unstructured":"Garg SK. Antibiotic misuse during COVID-19 pandemic: a recipe for disaster. Indian J Crit Care Med. 2021;25:617.","journal-title":"Indian J Crit Care Med"},{"key":"7993_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000515067","volume":"4","author":"VL Nag","year":"2021","unstructured":"Nag VL, Kaur N. Superinfections in COVID-19 patients: role of antimicrobials. Dubai Med J. 2021;4:117\u201326.","journal-title":"Dubai Med J"},{"key":"7993_CR28","doi-asserted-by":"publisher","first-page":"106324","DOI":"10.1016\/j.ijantimicag.2021.106324","volume":"57","author":"CC Lai","year":"2021","unstructured":"Lai CC, Chen SY, Ko WC, Hsueh PR. Increased antimicrobial resistance during the COVID-19 pandemic. J Antimicrob Agents. 2021;57:106324.","journal-title":"J Antimicrob Agents"},{"key":"7993_CR29","doi-asserted-by":"publisher","first-page":"ofaa220","DOI":"10.1093\/ofid\/ofaa220","volume":"7","author":"Y Fu","year":"2020","unstructured":"Fu Y, Yang Q, Xu M, Kong H, Chen H, Fu Y, et al. Secondary bacterial infections in critical Ill patients with Coronavirus Disease 2019. Open Forum Infect Dis. 2020;7:ofaa220.","journal-title":"Open Forum Infect Dis"},{"key":"7993_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13756-020-00819-1","volume":"9","author":"J Li","year":"2020","unstructured":"Li J, Wang J, Yang Y, Cai P, Cao J, Cai X, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control. 2020;9:153.","journal-title":"Antimicrob Resist Infect Control"},{"key":"7993_CR31","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1080\/17474124.2018.1496017","volume":"12","author":"S Flores-Trevi\u00f1o","year":"2018","unstructured":"Flores-Trevi\u00f1o S, Mendoza-Olazar\u00e1n S, Bocanegra-Ibarias P, Maldonado-Garza HJ, Garza-Gonz\u00e1lez E. Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol. 2018;12:819\u201327.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"7993_CR32","first-page":"1","volume":"20","author":"A Yacouba","year":"2021","unstructured":"Yacouba A, Olowo-Okere A, Yunusa I. Repurposing of antibiotics for clinical management of COVID-19: a narrative review. Ann Clin Microbiol. 2021;20:1\u20138.","journal-title":"Ann Clin Microbiol"},{"key":"7993_CR33","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s40261-020-00933-3","volume":"40","author":"N Bleyzac","year":"2020","unstructured":"Bleyzac N, Goutelle S, Bourguignon L, Tod M. Azithromycin for COVID-19: more than just an Antimicrobial? Clin Drug Investig. 2020;40:683\u20136.","journal-title":"Clin Drug Investig"},{"key":"7993_CR34","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1128\/AAC.37.10.2080","volume":"37","author":"R Fass","year":"1993","unstructured":"Fass R. Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. Antimicrob Agents Chemother. 1993;37:2080\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"7993_CR35","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41575-021-00449-x","volume":"18","author":"E Tshibangu-Kabamba","year":"2021","unstructured":"Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance from biology to clinical implications. Nat Rev Gastroenterol Hepatol. 2021;18:613\u201329.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7993_CR36","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.arcmed.2020.06.004","volume":"51","author":"I Karampela","year":"2020","unstructured":"Karampela I, Dalamaga M. Could respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, prove to be beneficial as an Adjunct Treatment in COVID-19? Arch Med Res. 2020;51:741\u20132.","journal-title":"Arch Med Res"},{"key":"7993_CR37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ajg.2019.09.001","volume":"20","author":"M Alboraie","year":"2019","unstructured":"Alboraie M, Elhossary W, Aly OA, Abbas B, Abdelsalam L, Ghaith D, et al. Egyptian recommendations for management of Helicobacter pylori infection: 2018 report. Arab J Gastroenterol. 2019;20:175\u20139.","journal-title":"Arab J Gastroenterol"},{"key":"7993_CR38","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","volume":"66","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Megraud F, O\u2019morain C, Gisbert J, Kuipers E, Axon A, et al. Management of Helicobacter pylori infection\u2014the Maastricht V\/Florence consensus report. Gut. 2017;66:6\u201330.","journal-title":"Gut"},{"key":"7993_CR39","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1053\/j.gastro.2020.11.059","volume":"160","author":"SC Shah","year":"2021","unstructured":"Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021;160:1831\u201341.","journal-title":"Gastroenterology"},{"key":"7993_CR40","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.21608\/ejhm.2022.258482","volume":"89","author":"SHN Taha","year":"2022","unstructured":"Taha SHN, Moawad AM, Ghazy RM, Abdelhalim WA. Assessment of self-treatment knowledge, beliefs and practice during COVID-19 pandemic among Egyptian population: a cross sectional study. Egypt J Hosp Med. 2022;89:4516\u201325.","journal-title":"Egypt J Hosp Med"},{"key":"7993_CR41","first-page":"1097","volume":"16","author":"S Kazemi","year":"2011","unstructured":"Kazemi S, Tavakkoli H, Habizadeh MR, Emami MH. Diagnostic values of Helicobacter pylori diagnostic tests: stool antigen test, urea breath test, rapid urease test, serology and histology. J Res Med Sci. 2011;16:1097\u2013104.","journal-title":"J Res Med Sci"},{"key":"7993_CR42","doi-asserted-by":"publisher","first-page":"940650","DOI":"10.1155\/2011\/940650","volume":"2011","author":"S Red\u00e9en","year":"2011","unstructured":"Red\u00e9en S, Petersson F, T\u00f6rnkrantz E, Levander H, M\u00e5rdh E, Borch K. Reliability of diagnostic tests for Helicobacter pylori infection. Gastroenterol Res Pract. 2011;2011:940650.","journal-title":"Gastroenterol Res Pract"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-07993-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-07993-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-07993-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T04:36:46Z","timestamp":1674275806000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-07993-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7993"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-07993-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"12 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol got approval by the Ethical Committee of the Faculty of Medicine, Alexandria University, Egypt (Approval Number: 00012098) and the study was performed following the good clinical practice and the ethical principles for the medical research involving human subjects of the Declaration of Helsinki. Written informed consent was obtained from each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}